Dr. Nguyen on Treatment Considerations in High-Risk Prostate Cancer


In Partnership With:

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Paul L. Nguyen, MD, senior physician and director of Genitourinary Clinical Center for Radiation Oncology at Dana-Farber Cancer Institute, as well as a professor of radiation oncology at Harvard Medical School, discusses treatment considerations in high-risk prostate cancer.

Patients with high-risk prostate cancer should be considered for radiation therapy plus a brachytherapy boost and 2 years of hormone therapy, Nguyen explains.

Patients who undergo a radical prostatectomy with unfavorable disease features should receive early salvage therapy without adjuvant therapy, Nguyen says.

In Nguyen’s practice, most patients with high-risk prostate cancer receive 6 months of hormone therapy plus salvage radiation.

However, for patients with favorable disease features such as pathologic T2 disease, a Gleason score of 7, a positive margin, and a very low prostate-specific antigen level, radiation therapy may be offered alone, as androgen deprivation therapy may provide little additive benefit, concludes Nguyen.

Related Videos
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Alessandro Di Federico, MD
Qian (Janie) Qin, MD
Judy C. Boughey, MD
Tian Zhang, MD, MHS
Francisco J. Esteva, MD, PhD
Related Content